In less than two weeks, there've been four pretty significant events in biopharma. And, hopefully, after ADA things will begin to settle down a bit for the summer.
We will have a full lineup of CEOs, execs and an analyst live from ADA. This time I don't think we'll have to fight for airtime like we did at ASCO because of the GM bankruptcy, Geithner in China, market rally and the sad, tragic missing airplane story. Genentech's Exec VP of Global Development and Chief Medical Officer even changed his flight to accomodate our crazy, fast-changing schedule. So, thanks for that.
By its very nature the news biz is unpredictable, so something can always destroy our best laid plans for ADA. Of course, it's never easy telling a CEO and/or his/her handler that because of circumstances beyond our control we have to cancel or try to reschedule their interview. Most (not all) of them want their and their company's moment in the spotlight and I certainly want to highlight as many important or good stories on my beat as I possibly can. I often try to fight the good fight, but you can't win 'em all and you have to choose your battles.
JPMorgan biotech analyst Cory Kasimov titles a research note to clients today, "Laissez Les Bon Temps Rouler at ADA."For those who don't speak French or aren't familiar with the phrase, I'll save you the time Googling or Binging www.bing.com . It means "Let the good times roll!" I won't be having any fun until my Monday workday is over and we head out for some good New Orleans grub. But Kasimov writes, "Relative to the just concluded and unusually quiet ASCO meeting, ADA may seem like Mardi Gras."He bullets pretty much all the stuff we're planning to highlight including the brewing battle between AMLN, Eli Lillyand Alkermes versus Novo Nordisk over a new type of longer-acting, non-insulin injectables, the battle of the bulge between Vivus, Orexigen and Arena Pharmaceuticalsover their late-stage developmental diet pills and the re-emergence of inhalable insulin from MannKind.
And speaking of MannKind, Rodman & Renshaw initiated coverage of MNKD today with an "Outperform" rating and $14 price target. Pfizer and Nektar Therapeutics threw in the towel on Exubera. LLY and NVO soonafter followed suit on their experimental inhalables. But Alfred Mann refused to give up. And now his product called "Afresa" is in front of the FDA. R&R headlines its research note, " All inhaled insulins are not created equal & why Afresa is not another Exubera."R&R makes a market in MNKD.
Mr. Mann will be one of our live guests on Monday.
But arguably the biggest interview of the day will be with Amylin CEO Dan Bradbury in his first appearance since Carl Icahn launched and won his proxy fight.
You can check out my interview with Mr. Bradbury's nemesis, Mr. Icahn, from today's "Power Lunch" right here.
Laissez Les Bon Temps Rouler!
Questions? Comments? Pharma@cnbc.com and follow me on Twitter at mhuckman